Caribou Biosciences Inc Cash Flow Conversion Efficiency
Caribou Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Caribou Biosciences Inc (CRBU) has a cash flow conversion efficiency ratio of -0.232x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.79 Million) by net assets ($98.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Caribou Biosciences Inc (2019–2025)
Cash flow conversion efficiency of Caribou Biosciences Inc from 2019 to 2025. This chart illustrates how Caribou Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Caribou Biosciences Inc (CRBU) share price today for real-time trading data and today's change.
Caribou Biosciences Inc Cash Flow Conversion Ratio Explained
Caribou Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Caribou Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Caribou Biosciences Inc ranked by their cash flow conversion efficiency. Also see CRBU market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sýn hf
IC:SYN
|
0.105x |
|
Chia Her Industrial Co Ltd
TW:1449
|
-0.040x |
|
DYPNF Co.Ltd
KQ:104460
|
-0.090x |
|
Casing Macron Technology Co Ltd
TWO:3325
|
0.008x |
|
Daedong Gear Co. Ltd
KQ:008830
|
0.067x |
|
Orbis AG
XETRA:OBS
|
0.202x |
|
Aarti Surfactants Limited
NSE:AARTISURF
|
0.091x |
|
Erbosan Erciyas Boru Sanayi Ve Ticaret AS
IS:ERBOS
|
0.013x |
Annual Cash Flow Conversion Efficiency for Caribou Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Caribou Biosciences Inc from 2019 to 2025. Review cash generation quality of Caribou Biosciences Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $122.17 Million | $-110.99 Million | -0.908x | -66.28% |
| 2024-12-31 | $252.95 Million | $-138.20 Million | -0.546x | -115.75% |
| 2023-12-31 | $368.40 Million | $-93.29 Million | -0.253x | +16.24% |
| 2022-12-31 | $300.87 Million | $-90.97 Million | -0.302x | -260.58% |
| 2021-12-31 | $387.82 Million | $-32.52 Million | -0.084x | -105.92% |
| 2020-12-31 | $-23.44 Million | $-33.22 Million | 1.417x | +133.05% |
| 2019-12-31 | $7.46 Million | $-32.01 Million | -4.289x | -- |
About Caribou Biosciences Inc
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD… Read more